Change from originator infliximab to biosimilar does not affect 1‐year outcome in children with inflammatory bowel disease
Switching from O-Rem to B-IFX has no impact on clinical or laboratory parameters over the subsequent year. Clinicians can reliably reassure patients and families that switching is safe.
Authors
- Jeffrey S. Hyams (ORCID: https://orcid.org/0000-0002-9769-236X)
- Michael B Brimacombe (ORCID: https://orcid.org/0000-0002-3276-9071)
- Viven Solomon (ORCID: https://orcid.org/0009-0001-3544-7182)
- Sydney Kuzoian
- Genesis Michel
Institutions
- University of Connecticut (US)
- Connecticut Children's Medical Center (US)
- Hartford Financial Services (United States)
Publication Details
- Journal
- JPGN Reports
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1002/jpr3.12134
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00